HeartBeam to Host Q3 2025 Conference Call on November 13

HeartBeam Inc. (NASDAQ: BEAT) has scheduled a conference call for Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to review the company's third quarter 2025 financial results and operational progress. The medical technology company will discuss performance for the quarter ended September 30, 2025, while also providing updates on regulatory advancements, commercial-readiness initiatives, and upcoming corporate milestones.

The conference call represents a significant opportunity for investors and stakeholders to gain insight into HeartBeam's progress in transforming cardiac care through its innovative technology platform. The company is developing the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from non-coplanar directions and synthesizing these signals into a comprehensive 12-lead ECG. This breakthrough technology has the potential to revolutionize how cardiac conditions are detected and monitored outside traditional medical facilities.

HeartBeam's regulatory progress includes FDA clearance received in December 2024 for arrhythmia assessment using its 3D ECG technology. The company's 12-Lead ECG synthesis software remains under FDA review, representing a critical regulatory milestone that could significantly expand the technology's clinical applications. The company maintains a robust intellectual property portfolio with over 20 issued patents related to its core technology enablement, providing substantial protection for its innovative approach to cardiac monitoring.

The implications of HeartBeam's technology extend beyond immediate financial performance to potentially transformative impacts on global healthcare delivery. By enabling portable, comprehensive cardiac monitoring outside medical facilities, the technology could improve early detection of cardiac conditions, reduce healthcare costs associated with hospital visits, and provide physicians with actionable heart intelligence to guide patient care decisions. The platform's ability to identify cardiac health trends and acute conditions remotely represents a significant advancement in telemedicine and remote patient monitoring capabilities.

Investors and industry observers can access additional information through the company's newsroom at https://ibn.fm/BEAT, which provides ongoing updates about HeartBeam's developments. The upcoming conference call will offer detailed insights into how the company is progressing toward commercializing its technology and establishing its position in the growing digital health and remote monitoring markets. The discussion of commercial-readiness activities will be particularly important for understanding the company's timeline for bringing its innovative cardiac monitoring solutions to market and the potential revenue opportunities these advancements represent.